Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

The hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer.

Das S, Samant RS, Shevde LA.

Int J Breast Cancer. 2012;2012:298623. doi: 10.1155/2012/298623. Epub 2011 Dec 1.

2.

Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastases.

Das S, Tucker JA, Khullar S, Samant RS, Shevde LA.

PLoS One. 2012;7(3):e34374. doi: 10.1371/journal.pone.0034374. Epub 2012 Mar 29.

3.

Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis.

Das S, Samant RS, Shevde LA.

J Biol Chem. 2011 Mar 18;286(11):9612-22. doi: 10.1074/jbc.M110.174920. Epub 2010 Dec 18.

4.

TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.

Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA.

Cancer Res. 2011 Feb 1;71(3):822-31. doi: 10.1158/0008-5472.CAN-10-2993. Epub 2010 Dec 28.

5.

Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clézardin P, Peyruchaud O.

PLoS One. 2010 Mar 17;5(3):e9741. doi: 10.1371/journal.pone.0009741.

6.

A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.

Sadanandam A, Futakuchi M, Lyssiotis CA, Gibb WJ, Singh RK.

BMC Cancer. 2011 Jul 20;11:304. doi: 10.1186/1471-2407-11-304.

7.

Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.

Jun AY, Kim HJ, Park KK, Son KH, Lee DH, Woo MH, Chung WY.

Invest New Drugs. 2014 Feb;32(1):1-13. doi: 10.1007/s10637-013-9969-0. Epub 2013 May 15.

PMID:
23673814
8.

Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment.

Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN.

Cancer Res. 2012 Feb 15;72(4):897-907. doi: 10.1158/0008-5472.CAN-11-2681. Epub 2011 Dec 20.

9.

Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.

Lee JH, Kim B, Jin WJ, Kim JW, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2014 Sep 1;91(1):51-60. doi: 10.1016/j.bcp.2014.06.005. Epub 2014 Jun 11.

PMID:
24929117
10.
11.

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.

Buijs JT, Stayrook KR, Guise TA.

Cancer Microenviron. 2011 Dec;4(3):261-81. doi: 10.1007/s12307-011-0075-6. Epub 2011 Jul 12.

12.

C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.

Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T.

Cancer Res. 2003 Aug 15;63(16):5028-33.

13.

Molecular mechanisms of tumor-bone interactions in osteolytic metastases.

Chirgwin JM, Guise TA.

Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78. Review.

PMID:
11186331
14.

Breast cancer-derived factors facilitate osteolytic bone metastasis.

Rose AA, Siegel PM.

Bull Cancer. 2006 Sep;93(9):931-43. Review.

15.

Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad.

Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, Foley J.

PLoS One. 2012;7(1):e30255. doi: 10.1371/journal.pone.0030255. Epub 2012 Jan 19.

16.

Parathyroid hormone-related protein and bone metastases.

Guise TA.

Cancer. 1997 Oct 15;80(8 Suppl):1572-80. Review.

PMID:
9362424
17.

Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Hussein O, Komarova SV.

J Cell Commun Signal. 2011 Jun;5(2):85-99. doi: 10.1007/s12079-011-0117-3. Epub 2011 Jan 19.

18.

Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.

Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A, Takigawa M.

J Bone Miner Res. 2006 Jul;21(7):1045-59.

19.

Osteolytic bone metastasis in breast cancer.

Yoneda T, Sasaki A, Mundy GR.

Breast Cancer Res Treat. 1994;32(1):73-84. Review.

PMID:
7819589
20.

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.

Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC.

Breast Cancer Res Treat. 2012 Oct;135(3):771-80. doi: 10.1007/s10549-012-2222-2. Epub 2012 Aug 29.

PMID:
22926264

Supplemental Content

Support Center